Abingdon Health (ABDX) Stock Overview

Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices in the United Kingdom, the United States, Canada, Europe, and internationally. The company provides Abingdon Simply Test, a range of self-tests in the field of fertility, health and well-being, infectious diseases, and drug testing; PCRD and PCRD FLEX, are nucleic acid lateral flow tests, which are used for rapid readouts post isothermal amplification; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2, as well as plant health tests; and nucleic acid lateral flow immunoassays. It also offers AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader; and Salistick, a rapid saliva-based pregnancy test. In addition, the company provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. Further, it offers regulatory consultancy services for businesses in the diagnostics sector. The company has a strategic collaboration with DeepVerge plc for the development, manufacturing, and commercialization of lateral flow tests; and Vatic Health Limited for the development, manufacturing, and commercialization of infectious disease lateral flow self-tests. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.